The medical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s demonstrating significant promise in clinical trials for addressing obesity. Unlike some current weight loss solutions, retatrutide appears to offer a more substantial decrease in body weight and benefit metabolic health, particula